The analyst writes that Viking Therapeutics and Structure Therapeutics are attractive ... The Street broadly expected the Redefine-1 trial of CagriSema to show ~25% weight loss, raising the ...
LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...
CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...
REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual ...
Mexico's President Claudia Sheinbaum said on Sunday that reason should prevail a day after her government and the U.S. announced tariffs against one another, raising her fist in the air as she ...
The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a currently approved medicine but still didn't surpass it. Since Ozempic blasted onto the stage in 2017 with ...
under the apparent theory that they would benefit from CagriSema’s results. Shares of Viking Therapeutics were up 8.8%, while the American depositary receipts of Structure Therapeutics rose 1.2%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback